Antengene announces xpovio® (selinexor) national health insurance service approval for reimbursement in south korea

- xpovio® is the first xpo1 inhibitor approved for reimbursement by south korea's national health insurance service (nhis) for the treatment of adult patients with relapsed/refractory multiple myeloma (r/r mm). - the approval of xpovio® by the nhis in south korea is the fourth national reimbursement in the antengene markets after mainland of china, australia and singapore.
KPTI Ratings Summary
KPTI Quant Ranking